Patents by Inventor John David Blyth

John David Blyth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITION 064
    Publication number: 20120177705
    Abstract: A pharmaceutical composition which comprises N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide with mannitol and/or microcrystalline cellulose is described.
    Type: Application
    Filed: March 21, 2012
    Publication date: July 12, 2012
    Applicant: ASTRAZENECA AB
    Inventors: John David Blyth, Andrew John Day, Kieran James Lennon
  • Composition 064
    Patent number: 8168221
    Abstract: A pharmaceutical composition which comprises N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide with mannitol and/or 5 microcrystalline cellulose is described.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: May 1, 2012
    Assignee: AstraZeneca AB
    Inventors: John David Blyth, Andrew John Day, Kieran James Lennon
  • COMPOSITION 064
    Publication number: 20090099203
    Abstract: A pharmaceutical composition which comprises N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide with mannitol and/or microcrystalline cellulose is described.
    Type: Application
    Filed: October 10, 2008
    Publication date: April 16, 2009
    Applicant: ASTRAZENECA AB
    Inventors: John David Blyth, Andrew John Day, Kieran James Lennon